Int J Clin Exp Pathol 2015;8(6):7594-7599 www.ijcep.com /ISSN:1936-2625/IJCEP0009013
Case Report Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature Yongjie Xue1, Qiulan Wang2, Xuejiao He1 Department of Pathology, San Ai Tang Hospital, Lanzhou, China; 2Clinical College, Gansu University of Chinese Tranditional Medicine, Lanzhou, China 1
Received April 12, 2015; Accepted May 27, 2015; Epub June 1, 2015; Published June 15, 2015 Abstract: Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses. We report a case of a 43-year-old patient who presented pain in the lower abdomen that had begun four months prior. Ultrasound-guided biopsy revealed epithelial cell features and a partial alveolar growth pattern. We discovered large diffuse areas comprising large cells with slightly irregular nuclei and very clear cytoplasm. These features were similar to those of clear cell carcinoma in renal tissue, suggesting the possibility of an epithelial neoplasm. To test this possibility, immunohistochemistry for cluster designation markers was performed, but the diffuse areas were found to be positive only for CD45. Additional immunohistochemistry was performed, and the diffuse areas were found to be positive for CD20, CD79a, P53, and Mum-1. Based on these characteristics, a diagnosis of a clear cell variant of DLBCL was made, and the patient was treated with chemotherapy. Precise histological diagnosis is crucial for clinical management and ultimately for patient survival. There has been one additional report of a case of clear cell DLBCL, in outside the mediastinum. The features we identified can be used to define a new subtype of DLBCL. The expression of P53 and Mum-1 suggest a poor prognosis. Keywords: Diffuse large B-cell lymphoma, retroperitoneal, CD45, CD20, clear cell, morphology, newly defined entities
Introduction Diffuse large B cell lymphoma (DLBCL), a subtype of non-Hodgkin’s lymphoma (NHL), is the most common type of lymphoid tumor worldwide, accounting for 30%-40% of adult NHLs, according to the World Health Organization’s (WHO) classification of neoplastic diseases of hematopoietic and lymphoid tissues [1]. DLBCL exhibits striking heterogeneity at the clinical, genetic, and molecular levels [2]. The tumor may arise as a primary tumor or as a result of the progression and transformation of a less aggressive lymphoma [3-5]. This heterogeneous group of lymphoid neoplasms is characterized by diverse spectra of clinical and morphological features [5], responses to therapy, and survival [6-9]. In partic-
ular, histological examination has revealed considerable morphological diversity. Morphological variants include the centroblastic, immunoblastic, and anaplastic subtypes, among which the centroblastic is the most common, with better prognosis and overall survival [10, 11]. Additional variants have been described, and new evidence supports their distinction as independent diseases [12]. The WHO (2008) working group delineated some of these newly defined entities [10] on the basis of their distinctive clinical, pathological, or biological features. Their recognition is helpful in defining a more homogeneous group of DLBCL. However, a large number of biologically and clinically heterogeneous cases remain for which there are no clear and accepted criteria for subclassification; these are collectively termed DLBCL, not otherwise specified (NOS).
A case report of diffuse large B-cell lymphoma with clear cell morphology been aggravated for half a month. The patient first experienced fatigue, dizziness, and discomfort 5 months before her admittance. The symptoms worsened after activity and could be relieved temporarily after rest. Upon symptomatic treatment provided by a local hospital, the symptoms disappeared. Then one month after the symptoms began, the patient experienced a dull pain in her lower abdomen and developed a mass at the site of the pain. Initially, the patient ignored the symptoms and did not seek medical treatment. Over time, the pain aggravated gradually and presented intermittent features accompanied by fatigue, dizziness, and discomfort. The patient also experienced occasional nausea but no abdominal distention, vomiting, or melena. Half a month before admission, she Figure 1. A. Computed tomography (CT) images. soft tissue mass beneath the lower and medial peritoneum. B. H&E staining. Sheets of large cells with received CT examination in a abundant clear cytoplasm and with distinct cell boundaries. Nuclei were local county hospital due to oval or irregular in shape and were deeply stained. Original magnification, × persistent and unbearable 200. C. Immunohistochemical staining. CD20+ expressed positivity. Original aggravated lower abdominal magnification, × 200. D. Immunohistochemical staining. Mum-1+ expressed Cell nuclei positiviy; original magnification, × 400. E. Immunohistochemical pain. The result of the CT stainig Ki-67+ expressed a high proliferation index (Ki-67 staining, 70%), examination indicated a maOriginal magnification × 200. ss in her lower abdomen. Her weight had decreased by 8 kg We present a case of primary DLBCL with clear since the onset of her condition. The patient cell morphology in the retroperitoneal space, reported no previous medical history and with a review of the literature. According to the denied history of familial infective or genetic results of immunohistochemistry (IHC), the disease. Upon admission, the patient had a patient presents non- germinal center B celltemperature of 36.4°C and blood pressure of like (non-GCB) DLBCL, suggesting a poor pro120/70 mmHg. Systemic superficial lymph gnosis. nodes were not enlarged. Her abdomen was soft and flat, but a hard and relatively fixed Case presentation mass with an irregular size of approximately 7 cm × 6 cm was palpated under the navel. The The patient was a 43-year-old woman who premass was tender without rebound tenderness. sented with the chief complaint of painful swellThe liver, spleen and bilateral kidneys were not ing in the lower abdominals. She was admitted palpated. Repeated abdominal CT detected a to the hospital due to complaints of fatigue, dizsoft tissue mass beneath the lower and medial ziness and intermittent lower abdominal pain peritoneum (Figure 1A). The mass wrapped the without obvious incentives. Symptoms had aorta, inferior vena cava and bifurcation area of begun 5 months before admittance and had the left and right iliac vessels. There was no 7595
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology obvious invasion in the vertebral body. The mass had a CT value of 44.0 HM, a maximum area of 5.28 cm × 4.27 cm, and unclear boundaries with the surrounding tissues. When enhanced scanning was performed, arterial phase enhancement was not obvious and the CT value was approximately 48.9 HM. The intraperitoneal lymph node was not enlarged. Plain film X-rays of the anteroposterior and lateral chest were normal without mediastinal enlargement. CT inspection revealed no masses in liver, kidney, lung, adrenal gland and brain. B ultrasound examination showed a homogeneous and relatively hypo-echoic area with a size of 6.2 cm × 3.5 cm around the abdominal aorta, behind the peritoneum and in front of the vertebral column. This area presented clear boundaries, a fairly regular shape, and regular internal echo. Blood routine examination, liver function testing, and biochemical testing found no abnormalities. B ultrasound-guided tumor puncture was performed two days after the patient was admitted to our hospital. A graywhite tissue with a length of 2 cm and a diameter of 2 mm was extracted. Conventional sectioning showed relatively homogeneous transparent cells that were analogous to renal clear cell carcinoma of medium size. Most cells were irregularly polygonal or ovoid in shape, with distinct cell boundaries and clear cytoplasm (Figure 1B). Nuclei were oval or irregular in shape and were deeply stained. Large nucleoli were observed in some of the nuclei. Massive necrosis accounted for 15% of the tumor tissue. A small number of fat cells were found in the tumor tissue without obvious interfibrillar substance. The preliminary consideration was an epithelial mesenchyme-derived malignant tumor. To test this possibility, IHC was carried out using antibodies for vimentin, Syn, CD34, CD117, S-100, HMB45, CKpan, CKlow, and CD45. CD45 was strongly expressed, but the tissue was negative for the rest of the epithelium and mesenchyme antibodies, suggesting that the tumor was not an epithelial mesenchyme-derived malignant tumor. Next, retroperitoneal lymphoma was considered, and a second round of IHC staining was performed. Antibodies were selected for their roles in the diagnosis and classification of lymphoma. Strong positive labeling was observed for CD20 (Figure 1C) and CD79a (+++) as well as for P53 and MUM-1 (++) (Figure 1D). In addition, approximately 70% of nuclei were positive for KI67 (Figure 1E). The tissue was negative for CD10, 7596
CD21, CD30, Bcl-2, bcl-6, CD3 and ALK. Based on these characteristics, we diagnosed the tumor as a clear cell variant of DLBCL, non-GCB type. R-CHOP was chosen as the clinical therapeutic protocol. Discussion DLBCL is a moderately to highly malignant B cell-derived tumor with significant heterogeneity. This heterogeneity is present not only in its complex and diverse clinical manifestations, histological features [4], immune phenotypes, and genetic characteristics, but also in the inconsistent responses of DLBCL patients to treatment and their different prognoses [5, 13, 14]. In the WHO classifications of 2001 and 2008 [15, 16], variants of DLBCL were defined according to the belief that they represent distinct clinico-pathologic entities [17]. As such, the pathomorphological changes found in tumors can be used for diagnostic purposes and to guide treatment. In the case we presented, the tumor cell morphology was different from that of common variants of DLBCL. Instead, the transparent and lightly stained tumor cell cytoplasm gave the initial impression that the condition was metastatic clear cell carcinoma or another clear cell tumor. This case suggests that the heterogeneity of DLBCL is greater than previously thought, as tumor cells can have morphological changes outside of those present in more common variants of DLBCL. Such differences in morphology present a great challenge for pathological diagnosis. Had no IHC techniques been applied, the pathological diagnosis in this case would have been incorrect. In pathological and differential tumor diagnosis, a variation of DLBCL should be considered after epithelial and mesenchymal tumors are excluded by IHC. This case emphasizes that correct pathological diagnosis requires the use of several pathological techniques, especially IHC. In diagnosing the tumor, we had to differentiate our case from other variants of DLBCL, including PMBCL. PMBCL is classified by the WHO and Maurizio Martelli classifications [18] as a subtype of DLBCL due to its distinct clinical presentation in younger patients, tumor site, and expression of CD30. PMBCL is thought to arise from asteroid B-cells of the thymus [19] and has often been recorded in young women presenting with a large mediastinal mass that freInt J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology quently invades adjacent structures and represents bulky disease [20]. PMBCL is morphologically heterogeneous, but is mainly composed of large cells with abundant, clear cytoplasm and round to ovoid nuclei. Diagnosis is further complicated by the occasional presence of ReedSternberg like cells, which raises the suspicion of classical Hodgkin lymphoma (CHL) [20]. We excluded a diagnosis of PMBCL when IHC showed the tumor cells were negative for the PMBCL marker CD30. A diagnosis of systemic DLBCL with secondary mediastinal involvement also had to be excluded. Dissemination outside the mediastinum commonly occurs in cases of relapse and involves extranodal sites such as the kidney, liver, adrenal glands, or central nervous system [20].
We performed a search of the literature worldwide and found a case reported by Suzana Manxhuka-Kerliu in 2011 [4]. Both this patient and the one in our case are at middle age and are pathologically typed as non-GCB.
The patient in this case was free from respiratory symptoms, and CT examination showed no tumor in the mediastinum, kidney, liver, adrenal glands, or central nervous system. In addition, IHC showed the tumor was negative for CD30. Based on these characteristics, the lesion was not considered to originate from the mediastinum, but was instead considered a retroperitoneal primary lesion. The diagnosis as a clear cell variant is indicative of a very significant morphological variation of DLBCL.
Disclosure of conflict of interest
Gene expression profile (GEP) studies have confirmed that DLBCL can be divided into subtypes according to its gene signature. These subtypes include germinal center B-cell (GCB) or GCB-like, activated B-cell (ABC) or ABC-like, and type 3 DLBCL [21, 22]. In addition to their specific gene signatures, these DLBCL subtypes are associated with different molecular signaling pathways and clinical outcomes [23, 24]. Patients with GCB-DLBCL have significantly better overall survival than those with ABCDLBCL [25, 26]. Because GEP is expensive and not readily available in routine practice, several algorithms [27, 28] have been proposed in recent years as alternative diagnostic tools for GEP. These algorithms have been based on IHC staining or tissue microarray analysis, which is a surrogate for GEP analysis [27, 28]. According to the Hans [9, 13] classification standard, the case we presented belonged to the non-GCB subtype of DLBCL due to the IHC staining results, which showed the tumor was negative for Bcl-2, Bcl-6, and CD10, and positive for Mum-1. This indicates a poor prognosis. 7597
Conclusion Based on our IHC findings, we diagnosed the present case as a clear cell variant of DLBCL of activated cell type, post-germinal center cell origin. Clear cell morphology is atypical of DLBCL, and may represent an otherwise unspecified variant of DLBCL. Our patient is alive and undergoing R-CHOP chemotherapy treatment. Due to time restrictions, the treatment has not been completed and further observation is required.
None. Address correspondence to: Dr. Yongjie Xue, Department of Pathology, San Ai Tang Hospital, 74 South Jingning Road, Lanzhou 730030, Gansu, P.R. China. Tel: +86-13919765305; Fax: +86-9318150897; E-mail: [email protected]
References [1]
[2]
[3]
[4]
[5]
[6]
Menon MP, Pittaluga S, Jaffe ES. The Histological and Biological Spectrum of Diffuse Large B-cell Lymphoma in the WHO Classification. Cancer J 2012; 18: 411-420. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164-1174. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De WolfPeeters C. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060-7068. Nayak PB, Desai D, Pandit S, Rai N. Centroblastic variant of diffuse large B-cell lymphoma: Case report and review of literature. J Oral Maxillo Pathol 2013; 17: 261-265. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology
[7]
[8]
[9]
[10]
[11]
[12]
[13] [14] [15]
[16]
B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284. Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 2014; 93: 1263-1277. Gurbuxani S, Anastasi J, Hyjek E. Diffuse large B-cell lymphoma-more than a diffuse collection of large b cells: An entity in search of a meaningful classification. Arch Pathol Lab Med 2009; 133: 1121-1134. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-5032. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edition. IARC, Lyon. Cultrera JL, Dalia SM. Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions. Cancer Control 2012; 19: 204-213. Dominis M, Dzebro S, Gasparov S, Pesut A, Kusec R. Diffuse large B-cell lymphoma and its variants. Croat Med J 2002; 43: 535-540. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In Pathology Genetics of Tumours of Haematopoietic and Lymphoid Tissues: IARC WHO Classification of Tumours. Volume 3. 3th edition. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Lyon, France: IARC Press; 2001. pp. 171-174. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. In
7598
[17]
[18]
[19] [20]
[21]
[22]
[23]
[24]
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). Volume 2. 4 edition. Geneva: World Health Organization; 2008. Terada T. Diffuse large B-cell lymphoma of nongerminal center B-cell type of the heart in an immunocompetent woman: an autopsy case. Med Oncol 2011; 28: 201-210. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171. Martelli M, Ferreri AJ, Johnson P. Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology 2008; 68: 256-263. Gaulard P, Harris NL, Pileri S, Kutok JL, Stein H, Kovrigina AM. Primary mediastinal, (thymic) large B-cell lymphoma. Arch Pathol Lab Med 2011; 135: 194-198. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 2002; 346: 1937-1947. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100: 9991-9996. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. [25] Song Y, Cao Z, Li L, Zhang HT, Zhang X. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation. Chin J Cancer 2010; 29: 781-786. [26] Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O’Connor OA. Novel disease targets and management approaches for diffuse large B cell lymphoma. Leuk Lymphoma 2010; 51: 1-10. [27] Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.
7599
[28] Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 54945502.
Int J Clin Exp Pathol 2015;8(6):7594-7599
Case Report Clear cell variant of diffuse large B-cell lymphoma: a case report and review of the literature Yongjie Xue1, Qiulan Wang2, Xuejiao He1 Department of Pathology, San Ai Tang Hospital, Lanzhou, China; 2Clinical College, Gansu University of Chinese Tranditional Medicine, Lanzhou, China 1
Received April 12, 2015; Accepted May 27, 2015; Epub June 1, 2015; Published June 15, 2015 Abstract: Diffuse large B cell lymphoma (DLBCL) is a diffuse proliferation of large neoplastic B lymphoid cells with nuclear size equal to or exceeding that of normal macrophage nuclei. The DLBCL morphological variants are centroblastic, immunoblastic, T-cell- and histiocyte-rich, anaplastic, plasmablastic, anaplastic lymphoma kinase-positive, and primary mediastinal large B-cell lymphoma (PMBCL). These histopathologically-recognized morphological variants respond differently to treatment and have distinct prognoses. We report a case of a 43-year-old patient who presented pain in the lower abdomen that had begun four months prior. Ultrasound-guided biopsy revealed epithelial cell features and a partial alveolar growth pattern. We discovered large diffuse areas comprising large cells with slightly irregular nuclei and very clear cytoplasm. These features were similar to those of clear cell carcinoma in renal tissue, suggesting the possibility of an epithelial neoplasm. To test this possibility, immunohistochemistry for cluster designation markers was performed, but the diffuse areas were found to be positive only for CD45. Additional immunohistochemistry was performed, and the diffuse areas were found to be positive for CD20, CD79a, P53, and Mum-1. Based on these characteristics, a diagnosis of a clear cell variant of DLBCL was made, and the patient was treated with chemotherapy. Precise histological diagnosis is crucial for clinical management and ultimately for patient survival. There has been one additional report of a case of clear cell DLBCL, in outside the mediastinum. The features we identified can be used to define a new subtype of DLBCL. The expression of P53 and Mum-1 suggest a poor prognosis. Keywords: Diffuse large B-cell lymphoma, retroperitoneal, CD45, CD20, clear cell, morphology, newly defined entities
Introduction Diffuse large B cell lymphoma (DLBCL), a subtype of non-Hodgkin’s lymphoma (NHL), is the most common type of lymphoid tumor worldwide, accounting for 30%-40% of adult NHLs, according to the World Health Organization’s (WHO) classification of neoplastic diseases of hematopoietic and lymphoid tissues [1]. DLBCL exhibits striking heterogeneity at the clinical, genetic, and molecular levels [2]. The tumor may arise as a primary tumor or as a result of the progression and transformation of a less aggressive lymphoma [3-5]. This heterogeneous group of lymphoid neoplasms is characterized by diverse spectra of clinical and morphological features [5], responses to therapy, and survival [6-9]. In partic-
ular, histological examination has revealed considerable morphological diversity. Morphological variants include the centroblastic, immunoblastic, and anaplastic subtypes, among which the centroblastic is the most common, with better prognosis and overall survival [10, 11]. Additional variants have been described, and new evidence supports their distinction as independent diseases [12]. The WHO (2008) working group delineated some of these newly defined entities [10] on the basis of their distinctive clinical, pathological, or biological features. Their recognition is helpful in defining a more homogeneous group of DLBCL. However, a large number of biologically and clinically heterogeneous cases remain for which there are no clear and accepted criteria for subclassification; these are collectively termed DLBCL, not otherwise specified (NOS).
A case report of diffuse large B-cell lymphoma with clear cell morphology been aggravated for half a month. The patient first experienced fatigue, dizziness, and discomfort 5 months before her admittance. The symptoms worsened after activity and could be relieved temporarily after rest. Upon symptomatic treatment provided by a local hospital, the symptoms disappeared. Then one month after the symptoms began, the patient experienced a dull pain in her lower abdomen and developed a mass at the site of the pain. Initially, the patient ignored the symptoms and did not seek medical treatment. Over time, the pain aggravated gradually and presented intermittent features accompanied by fatigue, dizziness, and discomfort. The patient also experienced occasional nausea but no abdominal distention, vomiting, or melena. Half a month before admission, she Figure 1. A. Computed tomography (CT) images. soft tissue mass beneath the lower and medial peritoneum. B. H&E staining. Sheets of large cells with received CT examination in a abundant clear cytoplasm and with distinct cell boundaries. Nuclei were local county hospital due to oval or irregular in shape and were deeply stained. Original magnification, × persistent and unbearable 200. C. Immunohistochemical staining. CD20+ expressed positivity. Original aggravated lower abdominal magnification, × 200. D. Immunohistochemical staining. Mum-1+ expressed Cell nuclei positiviy; original magnification, × 400. E. Immunohistochemical pain. The result of the CT stainig Ki-67+ expressed a high proliferation index (Ki-67 staining, 70%), examination indicated a maOriginal magnification × 200. ss in her lower abdomen. Her weight had decreased by 8 kg We present a case of primary DLBCL with clear since the onset of her condition. The patient cell morphology in the retroperitoneal space, reported no previous medical history and with a review of the literature. According to the denied history of familial infective or genetic results of immunohistochemistry (IHC), the disease. Upon admission, the patient had a patient presents non- germinal center B celltemperature of 36.4°C and blood pressure of like (non-GCB) DLBCL, suggesting a poor pro120/70 mmHg. Systemic superficial lymph gnosis. nodes were not enlarged. Her abdomen was soft and flat, but a hard and relatively fixed Case presentation mass with an irregular size of approximately 7 cm × 6 cm was palpated under the navel. The The patient was a 43-year-old woman who premass was tender without rebound tenderness. sented with the chief complaint of painful swellThe liver, spleen and bilateral kidneys were not ing in the lower abdominals. She was admitted palpated. Repeated abdominal CT detected a to the hospital due to complaints of fatigue, dizsoft tissue mass beneath the lower and medial ziness and intermittent lower abdominal pain peritoneum (Figure 1A). The mass wrapped the without obvious incentives. Symptoms had aorta, inferior vena cava and bifurcation area of begun 5 months before admittance and had the left and right iliac vessels. There was no 7595
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology obvious invasion in the vertebral body. The mass had a CT value of 44.0 HM, a maximum area of 5.28 cm × 4.27 cm, and unclear boundaries with the surrounding tissues. When enhanced scanning was performed, arterial phase enhancement was not obvious and the CT value was approximately 48.9 HM. The intraperitoneal lymph node was not enlarged. Plain film X-rays of the anteroposterior and lateral chest were normal without mediastinal enlargement. CT inspection revealed no masses in liver, kidney, lung, adrenal gland and brain. B ultrasound examination showed a homogeneous and relatively hypo-echoic area with a size of 6.2 cm × 3.5 cm around the abdominal aorta, behind the peritoneum and in front of the vertebral column. This area presented clear boundaries, a fairly regular shape, and regular internal echo. Blood routine examination, liver function testing, and biochemical testing found no abnormalities. B ultrasound-guided tumor puncture was performed two days after the patient was admitted to our hospital. A graywhite tissue with a length of 2 cm and a diameter of 2 mm was extracted. Conventional sectioning showed relatively homogeneous transparent cells that were analogous to renal clear cell carcinoma of medium size. Most cells were irregularly polygonal or ovoid in shape, with distinct cell boundaries and clear cytoplasm (Figure 1B). Nuclei were oval or irregular in shape and were deeply stained. Large nucleoli were observed in some of the nuclei. Massive necrosis accounted for 15% of the tumor tissue. A small number of fat cells were found in the tumor tissue without obvious interfibrillar substance. The preliminary consideration was an epithelial mesenchyme-derived malignant tumor. To test this possibility, IHC was carried out using antibodies for vimentin, Syn, CD34, CD117, S-100, HMB45, CKpan, CKlow, and CD45. CD45 was strongly expressed, but the tissue was negative for the rest of the epithelium and mesenchyme antibodies, suggesting that the tumor was not an epithelial mesenchyme-derived malignant tumor. Next, retroperitoneal lymphoma was considered, and a second round of IHC staining was performed. Antibodies were selected for their roles in the diagnosis and classification of lymphoma. Strong positive labeling was observed for CD20 (Figure 1C) and CD79a (+++) as well as for P53 and MUM-1 (++) (Figure 1D). In addition, approximately 70% of nuclei were positive for KI67 (Figure 1E). The tissue was negative for CD10, 7596
CD21, CD30, Bcl-2, bcl-6, CD3 and ALK. Based on these characteristics, we diagnosed the tumor as a clear cell variant of DLBCL, non-GCB type. R-CHOP was chosen as the clinical therapeutic protocol. Discussion DLBCL is a moderately to highly malignant B cell-derived tumor with significant heterogeneity. This heterogeneity is present not only in its complex and diverse clinical manifestations, histological features [4], immune phenotypes, and genetic characteristics, but also in the inconsistent responses of DLBCL patients to treatment and their different prognoses [5, 13, 14]. In the WHO classifications of 2001 and 2008 [15, 16], variants of DLBCL were defined according to the belief that they represent distinct clinico-pathologic entities [17]. As such, the pathomorphological changes found in tumors can be used for diagnostic purposes and to guide treatment. In the case we presented, the tumor cell morphology was different from that of common variants of DLBCL. Instead, the transparent and lightly stained tumor cell cytoplasm gave the initial impression that the condition was metastatic clear cell carcinoma or another clear cell tumor. This case suggests that the heterogeneity of DLBCL is greater than previously thought, as tumor cells can have morphological changes outside of those present in more common variants of DLBCL. Such differences in morphology present a great challenge for pathological diagnosis. Had no IHC techniques been applied, the pathological diagnosis in this case would have been incorrect. In pathological and differential tumor diagnosis, a variation of DLBCL should be considered after epithelial and mesenchymal tumors are excluded by IHC. This case emphasizes that correct pathological diagnosis requires the use of several pathological techniques, especially IHC. In diagnosing the tumor, we had to differentiate our case from other variants of DLBCL, including PMBCL. PMBCL is classified by the WHO and Maurizio Martelli classifications [18] as a subtype of DLBCL due to its distinct clinical presentation in younger patients, tumor site, and expression of CD30. PMBCL is thought to arise from asteroid B-cells of the thymus [19] and has often been recorded in young women presenting with a large mediastinal mass that freInt J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology quently invades adjacent structures and represents bulky disease [20]. PMBCL is morphologically heterogeneous, but is mainly composed of large cells with abundant, clear cytoplasm and round to ovoid nuclei. Diagnosis is further complicated by the occasional presence of ReedSternberg like cells, which raises the suspicion of classical Hodgkin lymphoma (CHL) [20]. We excluded a diagnosis of PMBCL when IHC showed the tumor cells were negative for the PMBCL marker CD30. A diagnosis of systemic DLBCL with secondary mediastinal involvement also had to be excluded. Dissemination outside the mediastinum commonly occurs in cases of relapse and involves extranodal sites such as the kidney, liver, adrenal glands, or central nervous system [20].
We performed a search of the literature worldwide and found a case reported by Suzana Manxhuka-Kerliu in 2011 [4]. Both this patient and the one in our case are at middle age and are pathologically typed as non-GCB.
The patient in this case was free from respiratory symptoms, and CT examination showed no tumor in the mediastinum, kidney, liver, adrenal glands, or central nervous system. In addition, IHC showed the tumor was negative for CD30. Based on these characteristics, the lesion was not considered to originate from the mediastinum, but was instead considered a retroperitoneal primary lesion. The diagnosis as a clear cell variant is indicative of a very significant morphological variation of DLBCL.
Disclosure of conflict of interest
Gene expression profile (GEP) studies have confirmed that DLBCL can be divided into subtypes according to its gene signature. These subtypes include germinal center B-cell (GCB) or GCB-like, activated B-cell (ABC) or ABC-like, and type 3 DLBCL [21, 22]. In addition to their specific gene signatures, these DLBCL subtypes are associated with different molecular signaling pathways and clinical outcomes [23, 24]. Patients with GCB-DLBCL have significantly better overall survival than those with ABCDLBCL [25, 26]. Because GEP is expensive and not readily available in routine practice, several algorithms [27, 28] have been proposed in recent years as alternative diagnostic tools for GEP. These algorithms have been based on IHC staining or tissue microarray analysis, which is a surrogate for GEP analysis [27, 28]. According to the Hans [9, 13] classification standard, the case we presented belonged to the non-GCB subtype of DLBCL due to the IHC staining results, which showed the tumor was negative for Bcl-2, Bcl-6, and CD10, and positive for Mum-1. This indicates a poor prognosis. 7597
Conclusion Based on our IHC findings, we diagnosed the present case as a clear cell variant of DLBCL of activated cell type, post-germinal center cell origin. Clear cell morphology is atypical of DLBCL, and may represent an otherwise unspecified variant of DLBCL. Our patient is alive and undergoing R-CHOP chemotherapy treatment. Due to time restrictions, the treatment has not been completed and further observation is required.
None. Address correspondence to: Dr. Yongjie Xue, Department of Pathology, San Ai Tang Hospital, 74 South Jingning Road, Lanzhou 730030, Gansu, P.R. China. Tel: +86-13919765305; Fax: +86-9318150897; E-mail: [email protected]
References [1]
[2]
[3]
[4]
[5]
[6]
Menon MP, Pittaluga S, Jaffe ES. The Histological and Biological Spectrum of Diffuse Large B-cell Lymphoma in the WHO Classification. Cancer J 2012; 18: 411-420. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005; 106: 1164-1174. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V, Praet M, De WolfPeeters C. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060-7068. Nayak PB, Desai D, Pandit S, Rai N. Centroblastic variant of diffuse large B-cell lymphoma: Case report and review of literature. J Oral Maxillo Pathol 2013; 17: 261-265. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Gaulard P, Coiffier B. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology
[7]
[8]
[9]
[10]
[11]
[12]
[13] [14] [15]
[16]
B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284. Carbone A, Gloghini A, Kwong YL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 2014; 93: 1263-1277. Gurbuxani S, Anastasi J, Hyjek E. Diffuse large B-cell lymphoma-more than a diffuse collection of large b cells: An entity in search of a meaningful classification. Arch Pathol Lab Med 2009; 133: 1121-1134. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-5032. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edition. IARC, Lyon. Cultrera JL, Dalia SM. Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions. Cancer Control 2012; 19: 204-213. Dominis M, Dzebro S, Gasparov S, Pesut A, Kusec R. Diffuse large B-cell lymphoma and its variants. Croat Med J 2002; 43: 535-540. Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In Pathology Genetics of Tumours of Haematopoietic and Lymphoid Tissues: IARC WHO Classification of Tumours. Volume 3. 3th edition. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Lyon, France: IARC Press; 2001. pp. 171-174. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. In
7598
[17]
[18]
[19] [20]
[21]
[22]
[23]
[24]
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (IARC WHO Classification of Tumours). Volume 2. 4 edition. Geneva: World Health Organization; 2008. Terada T. Diffuse large B-cell lymphoma of nongerminal center B-cell type of the heart in an immunocompetent woman: an autopsy case. Med Oncol 2011; 28: 201-210. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171. Martelli M, Ferreri AJ, Johnson P. Primary mediastinal large B-cell lymphoma. Critical Reviews in Oncology/Hematology 2008; 68: 256-263. Gaulard P, Harris NL, Pileri S, Kutok JL, Stein H, Kovrigina AM. Primary mediastinal, (thymic) large B-cell lymphoma. Arch Pathol Lab Med 2011; 135: 194-198. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 2002; 346: 1937-1947. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100: 9991-9996. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, López-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM; Lymphoma/Leukemia Molecular Profiling
Int J Clin Exp Pathol 2015;8(6):7594-7599
A case report of diffuse large B-cell lymphoma with clear cell morphology Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947. [25] Song Y, Cao Z, Li L, Zhang HT, Zhang X. Blimp-1 protein and Hans classification on prognosis of diffuse large B-cell lymphoma and their interrelation. Chin J Cancer 2010; 29: 781-786. [26] Wilson WH, Hernandez-Ilizaliturri FJ, Dunleavy K, Little RF, O’Connor OA. Novel disease targets and management approaches for diffuse large B cell lymphoma. Leuk Lymphoma 2010; 51: 1-10. [27] Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, Tzankov A, Wen W, Liu WM, Kahl BS, d’Amore ES, Montes-Moreno S, Dybkær K, Chiu A, Tam W, Orazi A, Zu Y, Bhagat G, Winter JN, Wang HY, O’Neill S, Dunphy CH, Hsi ED, Zhao XF, Go RS, Choi WW, Zhou F, Czader M, Tong J, Zhao X, van Krieken JH, Huang Q, Ai W, Etzell J, Ponzoni M, Ferreri AJ, Piris MA, Møller MB, Bueso-Ramos CE, Medeiros LJ, Wu L, Young KH. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103-2113.
7599
[28] Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, Braziel RM, Geng H, Iqbal J, Lenz G, Vose JM, Hans CP, Fu K, Smith LM, Li M, Liu Z, Gascoyne RD, Rosenwald A, Ott G, Rimsza LM, Campo E, Jaffe ES, Jaye DL, Staudt LM, Chan WC. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009; 15: 54945502.
Int J Clin Exp Pathol 2015;8(6):7594-7599
